Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why I Bought More of This Under-the-Radar Stock

TheMotleyFool

0 0

Why I Bought More of This Under-the-Radar Stock: https://g.foolcdn.com/editorial/images/693791/covid-test.jpg

Fulgent Genetics (NASDAQ: FLGT) was one of the first companies to develop a PCR COVID-19 test and it has been highly lucrative. In this segment of "Backstage Pass" on Motley Fool Live, recorded on July 27, Fool.com contributors Matt Frankel and Jason Hall discuss some of the reasons why it could be a good time to invest in the business.

Source Fool.com

Like: 0

FLGT

Share